Workflow
Standby Equity Purchase Agreement (SEPA)
icon
Search documents
Icon Energy Corp. Announces Updates in Connection with the SEPA
Globenewswire· 2025-11-24 14:28
Core Viewpoint - Icon Energy Corp. has successfully sold 132,144 shares under the Standby Equity Purchase Agreement (SEPA) at an average price of $1.86 per share, indicating a strategic move to raise capital for growth opportunities [1][2][3] Group 1: SEPA Details - Icon entered into the SEPA with an investor on August 27, 2025, allowing the company to issue up to $20 million worth of common shares over three years [2] - The SEPA provides Icon with a flexible and efficient source of capital, enabling the company to pursue growth opportunities and support strategic initiatives [3] Group 2: Company Overview - Icon Energy Corp. is an international shipping company that specializes in worldwide seaborne transportation services for dry bulk cargoes through its fleet of oceangoing vessels [3] - The company is headquartered in Athens, Greece, and its common shares are traded on the Nasdaq Capital Market under the symbol "ICON" [3]
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
Globenewswire· 2025-07-31 23:30
Core Viewpoint - MediciNova, Inc. has announced a Standby Equity Purchase Agreement (SEPA) allowing the company to raise up to $30 million in common stock over 36 months to support its R&D initiatives and general corporate activities [1][2][3]. Group 1: SEPA Details - The SEPA allows MediciNova to sell its common stock at a price equal to 97% of the market price, with the right to sell up to 100% of the daily trading volume during the five days prior to the transaction [2][4]. - The proceeds from the SEPA will be utilized to advance R&D programs and for general corporate purposes [2][3]. Group 2: Company Strategy and Focus - MediciNova is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, primarily targeting the U.S. market [5]. - The company is concentrating its development efforts on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic and metabolic disorders [5].